-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The fairness of medical insurance affects the survival of cancer patients The director of the medical insurance service of Peking University Cancer Hospital said that in recent years, the reform and innovation of china's medical insurance in the field of anti-cancer has greatly improved the protection of cancer patients.
2017 through the introduction of innovative forms of national negotiations and value of medical evidence, the health care catalog added 36 innovative drugs, in 2018 the special negotiations on cancer drugs added 17 special effects drugs, 2019 health insurance catalog added another clinically necessary innovative drugs 97.
among them, there is no shortage of quercturt bead monoanti, ketini, such as heavy bomb anti-cancer drugs, the national health insurance for breast cancer, lung cancer and other large cancer species to a new level of protection.
" This year the reform of medical insurance has entered a new stage, the latest implementation of the "Interim Measures for the Administration of Basic Medical Insurance Drugs", the national medical insurance drug catalogue formulation and adjustment has made a clear statement, and clearly put forward in line with the "clinical necessities, safe and effective, reasonable price" as the basic inclusion conditions.
, the dimension of fairness is attracting more and more attention from the society.
" Cold Jiaxuan explained that at present, from the perspective of the payer to the value of drugs outside the catalog, the first should evaluate the clinical value of drugs, for clinically necessary and proven safe and effective drugs, usually using the "cost-benefit" analysis method to further evaluate whether it is economical.
is to select funds to invest in drugs with the same but higher health benefits.
Through three consecutive years of dynamic adjustment of the health insurance catalog, some diseases have been better protected, while occupying more health insurance funds, but also some diseases are currently available to less special effects drugs, consumption of less health care resources, so it has triggered a discussion of the unfair sharing of health insurance resources for insured people.
The World Health Organization's GPS-HEALTH notes that the fairness of health insurance policy can be clearly divided into vertical equity and horizontal equity: horizontal equity refers to the provision of equal and consistent coverage for different patients with the same disease, depending on the characteristics of the population.
longitudinal equity refers to the fair protection between different diseases or subtypes of the same disease, depending on the characteristics of the disease.
of horizontal equity is relatively easy to solve, and the issue of vertical equity is now more prominent.
has a lot to do with the level of medical science and technology development, and policy guidance is needed to reduce the impact of vertical equity in health care.
" In recent years, the national anti-cancer drug medical insurance reimbursement has made a great reform, the original patient treatment of a course of treatment needs to use cancer drugs need hundreds of thousands of yuan, after medical insurance negotiations down to about 100,000 yuan or even lower, and then after medical insurance reimbursement, patients only bear about tens of thousands of yuan, which reflects the government's concern for the people.
, we should actively promote the establishment of a dynamic adjustment mechanism for health insurance to ensure the fairness and rationality of the use of health insurance funds.
more innovative anti-cancer drugs into medicare reimbursement, so that the pain of anti-cancer gradually become history.
, " said Professor Zhong Mingkang, director of the Department of Pharmacy at Huashan Hospital, affiliated with Fudan University.
is urgent to improve the access of innovative drugs" breast cancer treatment is the best example.
Ma Fei of the Oncology Hospital of the Chinese Academy of Medical Sciences is impressed by the fact that breast cancer is the number one cancer among women, with 4 deaths diagnosed every minute worldwide.
, the five-year survival rate of breast cancer patients in China has reached 83.2%, but the situation of diagnosis and treatment of advanced breast cancer is still very serious, the five-year survival rate of patients is only 20%.
the reason, China still has less access to innovative drug treatments than developed countries, and the innovative drugs already approved in China still face costly and unaffordable problems.
many patients in China give up treatment, the overall rate of treatment of advanced breast cancer is lower than in Europe and the United States.
and current health care policy, HER2-positive breast cancer patients have a clear advantage in Medicare reimbursement.
Therefore, the recently released Guidelines for the Standard Diagnosis and Treatment of Advanced Breast Cancer in China (2020 Edition) pay more attention to the progress of treatment of advanced breast cancer at home and abroad from 2018 to 2020, and in the field of treatment of HR-positive HER2-negative advanced breast cancer, the new version of the guidelines recommends the treatment of CDK4/6 inhibitors combined endocrine drugs.
update of the guidelines provides the basis for health policy development and allocation of health insurance resources for national health authorities to improve access to innovative drugs for advanced breast cancer at the national level for the benefit of more patients.
Because each hospital's discipline focus is different, there will be great differences in the clinical access of medical insurance drugs to hospitals, and the scientific drug evaluation and selection system also affects the accessibility and fairness of medical insurance drugs for cancer patients.
Professor Zhao Zhigang, Director of Pharmacy Department of Beijing Tiantan Hospital affiliated with Capital Medical University, introduced at the meeting that the release of the latest edition of the Rapid Guide to Drug Evaluation and Selection in Chinese Medical Institutions provides a scientific, fair and just way for medicines to enter hospitals after the publication of the National Health Insurance Directory, so that medical insurance drugs can be used quickly in clinical practice.
The Guidelines are formulated by experts in clinical pharmacy, clinical medicine, medical insurance, health economics and other fields, and are scored on more than 20 quantitative indicators based on the pharmaceutical characteristics, effectiveness, safety, economy and five other aspects of the drug, and the drugs that can be entered into the hospital are finalized on the basis of the scores.
process will also take into account the accessibility and fairness of Medicare anti-cancer drugs, so that more patients with different types of cancer can enjoy the best treatment.
multi-dimensional evaluation of the Guide will in turn promote continuous improvement and innovation, further improve the quality of medicines, and benefit patients.
reimbursement appears to be an act of reducing the burden of disease, but it can quickly be fed back into clinical treatment and research.
Fudan University affiliated oncology hospital director professor Yan Qing said: "Clear efficacy of new targeted drugs into health care, can not only reduce the burden on patients, but also improve patient compliance, so that the quality of life and survival rate of cancer patients to improve, such as HER2 positive monoantigen This not only affects the investment of drug research and development, but also contributes to the development of disciplines, but to think at many latitudes, taking breast cancer as an example, pathological subtypes are different treatment strategies, so the inclusion of fair evaluation into one of the comprehensive evaluation dimensions of anti-tumor drugs will bring survival benefits to more cancer patients.
" will be fair into the medical insurance drug evaluation system Beijing Rare Diseases Diagnosis and Health Care and Security Institute Liu Junshuai Vice President believes that the number of new drugs on the market more and more, some rare diseases before no good drugs and now have, this is "snow to send carbon";
, however, the limited size of the health insurance fund, the fairness of the system does not mean the maximum access to innovative drugs, the preferred choice itself contains the connotation of fair protection.
fact, as the core issue of drug protection for rare diseases, fair protection should be reflected in many aspects, such as ethics and efficiency.
From the point of view of system construction, compared with inclusive medical insurance, rare diseases (including rare diseases in different contexts) should have a relatively priority, relatively independent drug protection mechanism, and the GSP policy and priority policy should be combined to promote the continuous improvement of drug access as far as possible, so as to achieve a more valuable and efficient high level of fair protection;
, we should also change the past hospital-based payment business model, and gradually to outpatient protection and the management of serious and slow diseases.
, there is also a need to make a breakthrough in innovative payment mechanisms, introducing value-based, financial-based risk-sharing mechanisms to make funds more efficient, benefit more patients, and achieve more efficient and value-based equity guarantees.
2020-2030 is the key decade to achieve China's cancer prevention and control goals, how to improve the five-year survival rate of cancer patients has become the key to overcome the goal, of which improving the fairness of health insurance is one of the important graspers.
To this end, Professor Cold Jiaxuan suggested that the assessment of the fairness of anti-cancer drugs can be combined with the current medical insurance emphasis on "clinically necessary, safe and effective, reasonable price" assessment criteria, after the treatment meets the safety and effectiveness of the second step of screening.
will adjust the existing "clinical effectiveness and safety-cost-benefit-budget impact" to "clinical effectiveness and safety-social equity-cost-benefit-budget impact".
specific approach can be referred to the experience of European countries with universal health insurance: the size of the benefits, how much resources are consumed, the severity of the disease can be combined with several indicators, the largest income, the least consumption of resources, the highest severity of the disease, to give higher health insurance reimbursement.
the absolute clinical benefits of a single drug may no longer be a passport to access, after referring to the equity dimension in the field of health care.
Really make health care fair and coordinated, give full play to the strategic purchase role of medical insurance funds, promote the coordinated development of high-quality medical security and medical services, strengthen the people's sense of access, happiness and security, and effectively promote the realization of the 2030 goal of healthy China.
.